Cellbricks Therapeutics, a pioneering biotechnology company focused on biofabricated human tissue implants, today announced it has secured €10 million in new financing to accelerate the development of its next-generation regenerative medicine programs. The funding package includes a €7 million seed round and over €3 million in non-dilutive funding, currently under negotiation, positioning the company to advance its lead adipose tissue implant program and expand preclinical research.

The new capital will support the initiation of up to three preclinical animal studies, generate translational data, and accelerate the development of biological alternatives to synthetic implants. These innovations aim to address complex soft tissue defects, enhance wound healing, and improve outcomes in trauma care, including applications in reconstructive surgery such as breast reconstruction.

“Our proprietary biofabrication platform enables the creation of vascularized human tissue implants, a critical step toward replacing or regenerating damaged tissue with biologically compatible alternatives,” said a spokesperson for Cellbricks Therapeutics. “This funding milestone allows us to accelerate preclinical validation, strengthen translational evidence, and lay the groundwork for longer-term ambitions, including 3D-bioprinted, viable human organs.”

The financing round was led by Silicon Roundabout Ventures, with participation from Germany’s Federal Agency for Breakthrough Innovation SPRIND, ACT Venture Partners, and existing investors, reflecting strong confidence in Cellbricks’ technology and its potential to transform regenerative medicine.

Cellbricks Therapeutics’ approach combines advanced tissue engineering with biofabrication techniques to produce vascularized, implantable human tissues. The company envisions a future where biofabricated tissue not only supports reconstructive procedures but also opens doors to organ-level regenerative solutions.

About Cellbricks Therapeutics
Cellbricks Therapeutics is a biotechnology company advancing the next generation of biofabricated human tissue implants. Using proprietary biofabrication technology, the company develops vascularized tissue constructs for reconstructive surgery, trauma care, and regenerative medicine, aiming to provide biologically compatible alternatives to synthetic implants.